Influx Healthtech Q4 FY26 Results: PAT Rs 2.1 Cr

Influx Healthtech Q4 FY26 results were declared on May 20, 2026. The company reported PAT of Rs 2.1 crore for the quarter ended March 31, 2026, up 16.7% YoY compared to Rs 1.8 crore in Q4 FY25. Revenue from operations stood at Rs 28.5 crore, up 17.8% YoY. Results are on a Consolidated basis. Influx Healthtech is a Healthcare Technology company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Influx Healthtech Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	28.5	24.2	+17.8%
Net Profit	2.1	1.8	+16.7%
Basis	Consolidated

Note: Q4 FY26 results declared May 20 2026. Healthcare technology solutions company. Verify from BSE/NSE audited filings before investment decisions.

Influx Healthtech Q4 FY26 Performance Analysis

The Influx Healthtech Q4 FY26 results reflect the company’s performance for the January to March 2026 quarter. The company delivered stable results in line with sector trends. Influx Healthtech operates in the Healthcare Technology sector, supported by India’s GDP growth above 6.5% and domestic demand momentum during FY26.

The 16.7% YoY PAT growth in Influx Healthtech Q4 FY26 reflects near-term profitability headwinds with management focus on cost management.

Screen the best stocks on the Univest Screener.

Key Factors Driving Influx Healthtech Q4 FY26 Results

Revenue Performance Q4 FY26

Influx Healthtech Q4 FY26 revenue of Rs 28.5 crore(up 17.8% YoY) reflects demand conditions in the Healthcare Technology sector during the January to March 2026 period. India’s macro environment with GDP above 6.5% and fiscal year-end demand supported business activity across sectors.

Profitability and Margin Analysis

The Influx Healthtech Q4 FY26 PAT of Rs 2.1 crore up 16.7% YoY. Sustaining and growing profitability will be the primary focus entering FY27.

FY27 Outlook

Following Influx Healthtech Q4 FY26 results, management guidance on FY27 revenue growth, margin improvement, and capital allocation will be key investor watchpoints. The Healthcare Technology sector continues to benefit from India’s long-term growth story, government policy support, and rising domestic consumption trends.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Influx Healthtech Q4 FY26